MedPath

Nasal Intermittent Positive Pressure Ventilation(NIPPV) vs Continuous Positive Airway Pressure for Respiratory Distress Syndrome

Not Applicable
Conditions
Nasal Intermittent Positive Pressure Ventilation
Nasal Continuous Positive Airway Pressure
Interventions
Device: NIPPV
Device: NCPAP
Registration Number
NCT03226977
Lead Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Brief Summary

In the past, several studies have compared the effects between nasal intermittent positive pressure ventilation(NIPPV) and nasal continuous positive airway pressure(NCPAP) on the incidence of intubation in preterm infants, and the results were inconsistent.The purpose of the present study was to compare NIPPV with NCPAP on the need for endotracheal ventilation and subsequent complications

Detailed Description

To this day, early use of noninvasive respiratory support strategies has been suggested to be the most effective pathway to reduce those risks. Nasal continuous positive airway pressure (NCPAP) and nasal intermittent positive pressure ventilation (NIPPV) are two widely used ways of noninvasive ventilation strategies in preterm infant. As compared with invasive ventilation, NCPAP reduces the risks abnormal neurodevelopment. However, there is only 60% success rate of avoiding intubation in the preterm neonate supported with NCPAP. Supplying with an intermittent peak pressure on NCPAP, NIPPV is considered as a strengthened version of NCPAP with increased flow delivery in the upper airway, increased minute volume and functional residual capacity and recruitment of collapsed alveoli, improved stability of the chest wall and reduced asynchrony of thoraco-abdominal movement,which have been proven to be crucial to decrease the incidences of invasive ventilation and death. However, studies have compared the effects between nasal intermittent positive pressure ventilation(NIPPV) and nasal continuous positive airway pressure(NCPAP) on the incidence of intubation in preterm infants, and the results were inconsistent.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • Gestational age (GA) is from 26 to 37 weeks;
  • Diagnosis of RDS. The diagnosis of respiratory distress syndrome(RDS) will be based on clinical manifestations (tachypnea, nasal flaring and or grunting) and chest X-ray findings;
  • RDS Silverman score>5;
  • Informed parental consent has been obtained.
Exclusion Criteria
  • Severe RDS requiring early intubation according to the American Academy of Pediatrics guidelines for neonatal resuscitation;
  • Major congenital malformations or complex congenital heart disease;
  • Group B hemolytic streptococcus pneumonia, septicemia, pneumothorax, pulmonary hemorrhage;
  • Cardiopulmonary arrest needing prolonged resuscitation;
  • Transferred out of the neonatal intensive care unit without treatment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NIPPVNIPPVNIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
NCPAPNCPAPNCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
Primary Outcome Measures
NameTimeMethod
intubation ratewithin 7 days

the infant is intubated ventilation

Secondary Outcome Measures
NameTimeMethod
Intraventricular hemorrhagewithin 28 days

the incidence of intraventricular hemorrhage

bronchopulmonary dysplasiaat a post-menstrual age of 36 weeks or at discharge

bronchopulmonary dysplasia was defined according to the National Institutes of Health consensus definition

Bayley Scales of Infant Developmentat 2 months old and 2 years old

scores of Bayley Scales of Infant Development

Neonatal necrotizing enterocolitis(NEC)within 7 days

the incidence of neonatal necrotizing enterocolitis(\>stage II);for NEC, Bell staging will be used

Trial Locations

Locations (1)

Department of Pediatrics, Daping Hospital, Third Military Medical University

🇨🇳

Chongqing, Chongqing, China

© Copyright 2025. All Rights Reserved by MedPath